Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

Safety concerns included a 58% rate of treatment-related adverse events, with severe cases like immune-related colitis and a ...

The second study presented at the SITC meeting focuses on a “next-generation” approach following TIL therapy, utilizing ...

High CD8-positive T cell infiltration is linked to shorter PFS in epithelial ovarian cancer patients treated with bevacizumab ...

Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.

1. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive-stage small-cell lung cancer. FDA. November 19, 2025. Accessed November 19, 2025.

The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...

This discussion provides an overview of current treatment standards and practical challenges in managing advanced gastric ...

This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...

This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...

Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ER visits and improving treatment ...